Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
OPERATING MARGIN
0.00%
OPERATING MARGIN AVG TTM
0.00%
OPERATING MARGIN AVG 3Y
0.00%
OPERATING MARGIN AVG 5Y
0.00%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Unicycive Therapeutics, Inc.
Market Cap
$112.94M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$112.57M
Operating Margin
-1220.49%
TTM Avg
-1443.83%
3Y Avg
-998.11%
5Y Avg
-830.42%
Market Cap
$113.77M
Operating Margin
-255.05%
TTM Avg
-370.20%
3Y Avg
-218.02%
5Y Avg
-145.34%
Market Cap
$113.89M
Operating Margin
-415175.00%
TTM Avg
-405687.50%
3Y Avg
-206404.23%
5Y Avg
-137602.82%
Market Cap
$114.46M
Operating Margin
-1054.82%
TTM Avg
-1057.23%
3Y Avg
-4752.68%
5Y Avg
-4082.42%
Market Cap
$110.30M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$115.67M
Operating Margin
-265.64%
TTM Avg
-359.98%
3Y Avg
-411.27%
5Y Avg
-4203.28%
Market Cap
$109.14M
Operating Margin
-754.08%
TTM Avg
-1999.61%
3Y Avg
-1887.55%
5Y Avg
-2072.97%
Market Cap
$116.76M
Operating Margin
-137.12%
TTM Avg
-134.83%
3Y Avg
-112.12%
5Y Avg
-90.73%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | $112.94M | 0.00% | 0.00% | 0.00% | 0.00% |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | -1220.49% | -1443.83% | -998.11% | -830.42% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -255.05% | -370.20% | -218.02% | -145.34% |
| Genelux Corporation (GNLX)vs › | $113.89M | -415175.00% | -405687.50% | -206404.23% | -137602.82% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | -1054.82% | -1057.23% | -4752.68% | -4082.42% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | 0.00% | 0.00% | 0.00% | 0.00% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | -265.64% | -359.98% | -411.27% | -4203.28% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | -754.08% | -1999.61% | -1887.55% | -2072.97% |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | -137.12% | -134.83% | -112.12% | -90.73% |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | 0.00% | -571.68% | -414.68% | -276.45% |
Gross Margin
0.0%
Operating Margin
0.0%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | -622.52% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | -584.02% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
